ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2310건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2114 | Terminated | A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study) | COVID-19 | Drug: RBT-9 (90 mg) Drug: 0.9% sodium chloride (normal saline) |
Phase 2 | Renibus Therapeutics, Inc. | INDUSTRY | 42 | All | 18 Years | New Smyrna Beach, FL, New Smyrna Beach, Florida, United States Berkley, MI, Berkley, Michigan, United States El Paso, TX, El Paso, Texas, United States Fort Worth, TX, Fort Worth, Texas, United States Houston, Houston, Texas, United States |
| 2113 | Unknown status | A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19 | Covid19 | Drug: Niclosamide suspension Other: Placebo |
Phase 3 | Imuneks Farma ilac San. Tic. A.S. | INDUSTRY | 200 | All | 18 Years | Akdeniz Universitesi Tıp Fakultesi Hastanesi, Antalya, Turkey Antalya E?itim ve Ara?tırma Hastanesi, Antalya, Turkey Gaziantep Universitesi Tıp Fakultesi Hastanesi, Gaziantep, Turkey Gaziosmanpa?a Taksim E?itim ve Ara?tırma Hastanesi, Istanbul, Turkey Dokuz Eylul Universitesi Hastanesi, ?zmir, Turkey ?zmir SBU Tepecik E?itim ve Ara?tırma Hastanesi, ?zmir, Turkey SBU Dr. Suat Seren Go?us Hastalıkları ve Cerrahisi E?itim ve Ara?tırma Hastanesi, ?zmir, Turkey ?zmir Katip Celebi Universitesi Ataturk E?itim ve Ara?tırma Hastanesi, ?zmir, Turkey |
| 2112 | Completed | A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19 | COVID-19 | Drug: Brilacidin Drug: Placebo Drug: Standard of Care (SoC) |
Phase 2 | Innovation Pharmaceuticals, Inc. | INDUSTRY | 120 | All | 18 Years ~ 80 Years | IPI Investigator Site, Winfield, Illinois, United States IPI Investigator Site, Toledo, Ohio, United States IPI Investigator Site, Barnaul, Russian Federation IPI Investigator Site, Moscow, Russian Federation IPI Investigator Site, Moscow, Russian Federation IPI Investigator Site, Moscow, Russian Federation IPI Investigator Site, Moscow, Russian Federation IPI Investigator Site, Nizniy Novgorod, Russian Federation IPI Investigator Site, Pushkin, Russian Federation IPI Investigator Site, Saint Petersburg, Russian Federation IPI Investigator Site, Saint Petersburg, Russian Federation IPI Investigator Site, Saint Petersburg, Russian Federation |
| 2111 | Unknown status | A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19 | COVID-19 | Biological: DXP604 | Phase 2 | Wuhan Institute of Biological Products Co., Ltd | INDUSTRY | 50 | All | 18 Years ~ 70 Years | |
| 2110 | Withdrawn | A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19 | Coronavirus | Biological: EQ001 Biological: EQ001 Placebo |
Phase 3 | Equillium, Biocon Limited | INDUSTRY | 0 | All | 18 Years | Inv Site CO01, Medellin, Colombia |
| 2109 | Completed | A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention | COVID-19 | Drug: Ivermectin Tablets Drug: Matching placebo tablets |
Phase 2 | MedinCell S.A, Violaine Desort-Henin, DVM | INDUSTRY | 400 | All | 18 Years ~ 65 Years | Medical Center Medic Ltd., Sofia, Bulgaria |
| 2108 | Completed | A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19) | Coronavirus Disease 2019 (COVID-19) | Drug: Placebo Drug: Prothione™ (6g) |
Phase 2 | Prothione, LLC | OTHER | 231 | All | 18 Years | Rinda Ubuzima, Kigali, Rwanda |
